Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-04-02 Purchase | 2024-04-03 6:50 pm | Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner | 485,250 | $0.76 | $368,790 | 11,227,923 (Direct) | View |
| 2024-02-08 Sale | 2024-02-09 4:33 pm | Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner | 1,000 | $0.64 | $640 | 2,754,109 (Indirect Direct) | View |
| 2024-01-11 Sale | 2024-01-16 6:16 pm | Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner | 4,235 | $0.85017 | $3,600 | 2,755,109 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
Ownership | 2024-04-03 6:48 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | GILEAD SCIENCES INC. 10% Owner | 0 | $0 | 6,860,223 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 4:38 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James CHIEF OPERATING OFFICER | 77,500 | $0 | 77,500 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 4:15 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Luptakova Katarina CHIEF MEDICAL OFFICER | 66,500 | $0 | 66,500 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 4:15 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 20,000 | $0 | 20,000 (Direct) | View |
| 2024-01-01 Option Award | 2024-01-03 4:15 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | Russo Rene PRESIDENT AND CEO | 177,000 | $0 | 177,000 (Direct) | View |
| 2023-09-05 Option Award | 2023-09-07 4:26 pm | N/A 2033-09-04 | Xilio Therapeutics Inc. | XLO | Luptakova Katarina Chief Medical Officer | 106,000 | $0 | 106,000 (Direct) | View |
Ownership | 2023-09-07 4:23 pm | N/A 2031-12-06 | Xilio Therapeutics Inc. | XLO | Luptakova Katarina Chief Medical Officer | 0 | $0 | 119,210 (Direct) | View |
| 2023-08-16 Option Award | 2023-08-18 8:45 pm | N/A 2033-08-15 | Xilio Therapeutics Inc. | XLO | Russo Rene CEO | 700,000 | $0 | 700,000 (Direct) | View |
| 2023-08-16 Option Award | 2023-08-18 8:40 pm | N/A 2033-08-15 | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James CHIEF OPERATING OFFICER | 300,000 | $0 | 300,000 (Direct) | View |
| 2023-08-16 Option Award | 2023-08-18 8:35 pm | N/A 2033-08-15 | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-08-16 Option Award | 2023-08-18 8:30 pm | N/A 2033-08-15 | Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | 136,500 | $0 | 136,500 (Direct) | View |
| 2023-08-03 Option Award | 2023-08-07 4:12 pm | N/A 2033-08-02 | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Operating Officer | 150,000 | $0 | 150,000 (Direct) | View |
Ownership | 2023-08-07 4:09 pm | N/A 2031-03-28 | Xilio Therapeutics Inc. | XLO | Frankenfield Christopher James Chief Operating Officer | 0 | $0 | 398,172 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-13 4:30 pm | N/A 2033-06-11 | Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-13 4:30 pm | N/A 2033-06-11 | Xilio Therapeutics Inc. | XLO | Heyman Tomas J. Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-13 4:30 pm | N/A 2033-06-11 | Xilio Therapeutics Inc. | XLO | Xu Yuan Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-13 4:30 pm | N/A 2033-06-11 | Xilio Therapeutics Inc. | XLO | Bonstein Sara Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-13 4:30 pm | N/A 2033-06-11 | Xilio Therapeutics Inc. | XLO | Rossi Christina Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-13 4:30 pm | N/A 2033-06-11 | Xilio Therapeutics Inc. | XLO | Clancy Paul J Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2023-04-01 Option Award | 2023-04-03 4:11 pm | N/A 2033-03-31 | Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 55,000 | $0 | 55,000 (Direct) | View |
| 2023-01-01 Option Award | 2023-01-04 4:14 pm | N/A 2032-12-31 | Xilio Therapeutics Inc. | XLO | Russo Rene CEO | 350,000 | $0 | 350,000 (Direct) | View |
| 2023-01-01 Option Award | 2023-01-04 4:11 pm | N/A 2032-12-31 | Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | 136,500 | $0 | 136,500 (Direct) | View |
| 2023-01-01 Option Award | 2023-01-04 4:09 pm | N/A 2032-12-31 | Xilio Therapeutics Inc. | XLO | English Edward C PRINCIPAL ACCOUNTING OFFICER | 24,000 | $0 | 24,000 (Direct) | View |
Ownership | 2022-11-16 4:16 pm | N/A N/A | Xilio Therapeutics Inc. | XLO | English Edward C Principal Accounting Officer | 0 | $0 | 79,399 (Direct) | View |
| 2022-09-15 Option Award | 2022-09-16 4:15 pm | N/A 2032-09-14 | Xilio Therapeutics Inc. | XLO | Heyman Tomas J. Director | 26,400 | $0 | 26,400 (Direct) | View |
| 2022-06-15 Option Award(A) | 2022-06-23 7:30 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | 20,000 | $0 | 20,000 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:31 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D | 20,000 | $0 | 20,000 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:30 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | Rossi Christina Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:30 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | Ross Michael Jay Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:30 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | Clancy Paul J Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:30 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | Xu Yuan Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:30 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | Bonstein Sara Director | 13,200 | $0 | 13,200 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 4:08 pm | N/A 2032-06-14 | Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director | 26,400 | $0 | 26,400 (Direct) | View |
| 2022-02-22 Option Award | 2022-02-24 5:30 pm | N/A 2032-02-21 | Xilio Therapeutics Inc. | XLO | Giovine Salvatore CHIEF FINANCIAL OFFICER | 49,500 | $0 | 49,500 (Direct) | View |